Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

Novo Nordisk (NVO) is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

He added that the US market relies heavily on generic drugs rather than branded products, which Novo Nordisk does not sell. Competitor Eli Lilly (LLY) recently announced a $27 billion investment ...

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...